Search Results for "canagliflozin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for canagliflozin. Results 11 to 14 of 14 total matches.
Sotagliflozin (Inpefa) for Heart Failure
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023 (Issue 1681)
is recommended for most patients with HF with
a reduced or preserved LVEF.4,5 Canagliflozin
(Invokana ...
The FDA has approved sotagliflozin (Inpefa –
Lexicon), an oral sodium-glucose cotransporter
1 and 2 (SGLT1/2) inhibitor, to reduce the risk of
hospitalization for heart failure (HF), urgent HF visits,
and cardiovascular death in adults with either HF
(with any left ventricular ejection fraction [LVEF]) or
type 2 diabetes, chronic kidney disease (CKD), and
other cardiovascular risk factors. Sotagliflozin is
the first dual SGLT1/2 inhibitor to be approved in the
US. Unlike SGLT2 inhibitors, it is not FDA-approved
to improve glycemic control in adults with type 2
diabetes....
Med Lett Drugs Ther. 2023 Jul 24;65(1681):114-6 doi:10.58347/tml.2023.1681b | Show Introduction Hide Introduction
Empagliflozin (Jardiance) for Heart Failure with Reduced Ejection Fraction
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021 (Issue 1636)
,
have been published. Table 1. FDA-Approved Indications of SGLT2 Inhibitors
Canagliflozin (Invokana)
▶ Treatment ...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance – Boehringer Ingelheim)
has been approved by the FDA for a third indication: to
reduce the risk of hospitalization for heart failure (HF)
and cardiovascular death in patients with heart failure
with reduced ejection fraction (HFrEF), with or without
type 2 diabetes. The SGLT2 inhibitor dapagliflozin
(Farxiga) was approved for the same indication in
2020. Empagliflozin has been granted breakthrough
therapy designation for treatment of patients with
heart failure with preserved ejection fraction...
In Brief: Finerenone (Kerendia) for Diabetic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
with an eGFR ≥30 mL/
min/1.73 m2
An SGLT2 inhibitor with proven renal benefits (canagliflozin,
dapagliflozin ...
Recently published guidelines from the American
Diabetes Association (ADA) and the Kidney Disease:
Improving Global Outcomes (KDIGO) Diabetes Work
Group recommend addition of the oral nonsteroidal
mineralocorticoid receptor antagonist (MRA)
finerenone (Kerendia) to standard treatment in
patients with type 2 diabetes and chronic kidney
disease (CKD).
Med Lett Drugs Ther. 2023 Jan 23;65(1668):15-6 doi:10.58347/tml.2023.1668e | Show Introduction Hide Introduction
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022 (Issue 1655)
the hyperkalemic effects
of ARBs, ACE inhibitors, potassium-sparing
diuretics, aliskiren, and canagliflozin ...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines for
treatment of VTE were updated in 2020 and 2021.